HFpEF
Cardiac Amyloidosis
About Us
About Us
Platform
- EchoGo® Platform
Contact Us
- Contact Us
- Customer support
Clinical Evidence
Use Cases

Webinars

Real-World AI for HFpEF & Amyloidosis: Unlocking Diagnostic Power from a Single Echo View | ASE 2025

Featuring expert insights from Mayo Clinic, The University of Chicago Medicine, and City of Hope, this session presents real-world case studies, customer implementation examples, and results from the 2025 landmark trial of the first FDA-cleared AI echo-based screening tool for Cardiac Amyloidosis.

Clinical-Deployment-of-EchoGo®-HFpEF-at-Northwestern--Initial-Experience

Clinical Deployment of Ultromics EchoGo® HFpEF Algorithm at Northwestern: Initial Experience

Akhil Narang M.D. Presents real world evidence from the integration of EchoGo® Heart Failure at Northwestern highlighting the improved diagnostic pathway of HFpEF and patient impact.

Comparison-of-EchoGo®-HFpEF-and-Clinical-Prediction-Models-at-Beth-Israel-Lahey-Health

Comparison of an Artificial Intelligence Heart Failure Detection Model and Clinical Prediction Models in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF)

Jordan Strom M.D. from Harvard Medical School and Beth Israel Lahey Health presents research on the performance of EchoGo® Heart Failure in comparison to HFA-PEFF and H2FPEF and the clinical impact this has on pateint treatment.